Analyst Yun Zhong from Wedbush maintained a Buy rating on Sarepta Therapeutics and keeping the price target at $35.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong has given his Buy rating due to a combination of factors that, in his view, keep Elevidys and Sarepta well positioned despite new RGX-202 data. He argues that the key readout from REGENXBIO mainly strengthens confidence in microdystrophin as a surrogate marker for clinical benefit, which should support all gene therapies using this mechanism, including Sarepta’s program.
He also notes that cross-trial comparisons are limited by RGX-202’s small sample size and still-uncertain regulatory path, while Elevidys has already demonstrated robust microdystrophin expression across age groups and longer-term functional benefit versus external controls. In addition, evolving comfort with enhanced immunosuppression regimens to manage safety risks is seen as favorable for broader Elevidys adoption over time, underlining his view of improved uptake from 2H26 onward and supporting his unchanged $35 price target.
Zhong covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, MoonLake Immunotherapeutics, and Passage Bio. According to TipRanks, Zhong has an average return of -9.2% and a 37.79% success rate on recommended stocks.
In another report released on May 7, Wells Fargo also maintained a Buy rating on the stock with a $38.00 price target.